May 2024 - With just 5 weeks until the start of the European Hematology Association congress (EHA) it’s time to plan your CML meeting schedule!
To make sure you don’t miss any important updates and discussions we have compiled a list of CML related sessions.
EHA 2024 Hybrid Congress – Overview of CML sessions
The EHA 2024 Hybrid meeting will take place from June 13-16 in Madrid (Spain). The program will be fully live-streamed on the congress platform and content will be available on-demand until August 15th.
There will be a wide-ranging program on CML this year with latest updates on CML management and an outlook on new treatment approaches:
- The Education Session on CML on June 14 from 8.00 – 9.30 CEST will provide you with an update on CML management including targeting pathways outside BCR::ABL1, new treatment paradigms improving QoL and an update on the ELN Recommendations 2024.
- During the Hematology-in-Focus Session on CML on June 14 from 9.45 – 10.45 CEST you will learn when alternative therapeutics are indicated, how to manage patients with CML in countries with limited resources and how to monitor CML patients during and after therapy.
- During a Thematic debate on June 15 from 8.00 – 8.45 CEST two experts will discuss advanced line drug therapies versus allogeneic stem cell transplantation.
- The Scientific Working Group Session ELN-EHA-SWG for CML on June 15 from 9.45 – 10.45 CEST will be dedicated to new therapeutic approaches, such as protac inhibition for BCR-aBL1, BCL2 family and potential stem cell inhibition.
- EHA also features two Oral sessions dedicated to CML on June 15 from 16.30 – 17.45 CEST (New diagnostic and prognostic tools for CML) and on June 16 from 11.30 - 12.45 CEST (Optimization and innovation in CML treatment)
There is also a Satellite Symposium on CML supported by Novartis that will take place on June 13 from 8.00 – 9.30 CEST before the start of the official EHA scientific program.
Download the CML session overview here
View the full EHA program here
We also expect exciting poster presentations on CML including conclusions of the global iCMLf CANDID study underscoring the importance of vaccination against COVID-19 for patients with CML.
The CML overview will be updated as soon as the posters and final oral sessions are confirmed.